View this email in your browser

FALL 2018
 

Greetings Colleagues,
 
We at the University of Illinois Cancer Center are keenly aware that advances require cooperation between patients, caregivers and community leaders to lead us closer to a cure. Moreover, our overall philosophy is that “research cures cancer” and we are therefore dedicated to providing promising new therapies for ALL patients.
 
Our investigators develop ways to prevent, diagnose, treat, manage and cure cancer through our growing portfolio of clinical trials. As a provider in our referral network, you are a vital link in this partnership. This communication will inform you of our open clinical trials. We encourage you to contact our Cancer Clinical Trials Intake Coordinator at 312-555-5112 or cancertrials@uic.edu if you identify a trial for which your patients might be eligible.  
 
We recognize that any relationship is built upon trust and ongoing communication. Please do not hesitate to contact us at rwinn@uic.edu or jhstew4@uic.edu if you would like for us to meet you at your practice location to discuss opportunities for further partnership.  We look forward to the opportunity to serve your patients.

Yours truly,

Robert A. Winn, MD
Director, University of Illinois Cancer Center

Associate Vice Chancellor for Community Based Practice
John H. Stewart, IV, MD, MBA
Associate Director for Clinical Research

Physician Executive, Oncology Service Line
CONTACT US

PHONE

312-555-5112



EMAIL
cancertrials@uic.edu



REFER A PATIENT
312-966-6914
cancer.uillinois.edu
Browse our list of enrolling clinical trials here
UI Cancer Center Investigator Initiated Clinical Trials
Below are unique UI Cancer Center clinical trials designed by our faculty that are currently enrolling patients (click on the study title for more info):

Hematological Malignancies
A Phase II Study of Intensity Modulated Total Marrow Irradiation (TMI) in Addition to Fludarabine/ Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes (BMT-05)
PI:  Damiano Rondelli, MD

Breast Cancer
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer (BTCRC-BRE15-016)
PI:  Oana Danciu, MD

Lung Cancer
Phase II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Non-small Cell Lung Cancer Who Progressed after First Line Chemotherapy (BTCRC-LUN15-017)
PI:  Lawrence Feldman, MD

Solid Tumors
Phase I Study of PAC-1 in the Treatment of Advanced Hematologic Malignancy or Solid Tumors (STM-03)
PI:  Oana Danciu, MD
UI Cancer Center Clinical Trial Highlights
Breast
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (AFT-38)
PI:  Kent Hoskins, MD
 
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy (S1418)
PI:  Oana Danciu, MD

Hematological Malignancies
Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome After Failure of a Hypomethylating Agent (OncoNova 04-30)
PI:  Irum Khan, MD

A Phase I/II Study Of Pomalidomide, Dexamethasone And Ixazomib Vs. Pomalidomide And Dexamethasone For Patients With Multiple Myeloma Refractory To Lenalidomide And Proteasome Inhibitor-Based Therapy
PI:  Patel Pritesh, MD

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
PI:  John Quigley, MD

 
Kidney
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
PI:  David Peace, MD

 
Urothelial
Phase III, open-label, randomized study comparing combination therapy of nivolumab plus ipilimumab, followed by nivolumab vs standard of care in with previously untreated unresectable or metastatic urothelial carcinoma (CA209901)
PI:  David Peace, MD

The University of Illinois Cancer Center is comprised of physicians and cancer researchers dedicated to pursuing health equity; working with the community in developing research and treatment options; and studying cancer disparities. We are part of the University of Illinois at Chicago and University of Illinois Hospital and Health Sciences System.

 
Contact us to find out more information or refer a patient.
UICancerCenter
UICancerCenter
cancer.uillinois.edu
Copyright © University of Illinois Cancer Center, All rights reserved.

Our mailing address is:
818 S Wolcott Ave. Chicago, IL 60612

Want to change how you receive these emails?
You unsubscribe from this list.